Sudeep Pharma Ltd to Hold Board Meeting Today; Earnings Call on 22 December 

Mumbai, December, 19, 2025: Sudeep Pharma Limited, a company engaged in pharmaceutical business and listed on NSE & BSE, has announced that the meeting of the Board of Directors of the Company will be held on Friday, 19 December 2025 to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and half-year ended 30 September 2025. The company notified the exchanges in this regard under the relevant regulatory framework. 

Board Meeting to Approve Q2 and H1 FY26 Financial Results 

Sudeep Pharma’s Board shall, inter alia, consider and take on record the unaudited financial results of the Company for the quarter and half year ended 30 September 2025. This is also a part of the company’s regular financial reporting cycle and is in compliance with disclosure requirements under Regulation 29 of the SEBI (LODR) Regulations, 2015. The result of the meeting shall be the formal announcement of financial results. 

Trading Window Closed from 28 November to 21 December 2025 

Pursuant to the results announcement, Sudeep Pharma Limited has notified that “the trading window” for its designated persons under the internal code has been closed with effect from Friday, November 28, 2025, and will remain closed until Sunday, December 21, 2025 (both days inclusive), which͏ is 48 hours after the decl͏aration of the un͏au͏dited financial res͏ults. This step follows the co͏mpany’s Code of Conduct of the Company, formulated pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, e͏nsuring compli͏ance du͏ring the se͏nsitive period. 

Earnings Call on 22 December to Review Q2FY26 Results 

Following of the Board meeting, an Analyst & Investor call has been scheduled by Sudeep Pharma Limited on Monday, 22 December 2025 at 11:30 a.m. The discussion will be confined to the operational and financial results for the quarter and six months ended 30 September 2025. The engagement will see top-level management with Director Mr Shanil Bhayani and Chief Financial Officer Mr Ketan Vyas representing the company. 

Shares Trade Higher, Gaining 0.65% in Early Trade 

Shares of Sudeep Pharma Ltd were trading at ₹678.55 as of 9:45 a.m. IST on 19 December, up by ₹4.40 or 0.65% from its previous close. The stock price of Sudeep Pharma opened at ₹680.00. The company has a market cap of ₹7.66 thousand crore and is trading at a price to earnings (P/E) ratio of 55.25. During the last 52 weeks, the stock price reached a high of ₹795.00 and a low of ₹631.45. 

The Board of Directors’ meeting to be held today is a critical milestone in the financial reporting of Sudeep Pharma Limited for Q2 and H1 FY26 and would be followed by a e earnings call on 22 December. Stakeholders may view the official results release and management commentary upon release, subject to the closing of the trading window timing in connection with the results announcement. 

Source: https://www.nseindia.com/get-quote/equity/SUDEEPPHRM/Sudeep-Pharma-Limited 

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.  

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.  

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations